{"classes":[{"categories":[{"measurements":[{"comment":"NA - upper limit was not estimable","groupId":"OG000","lowerLimit":"5.55","upperLimit":"NA","value":"8.21"},{"comment":"NA - median, lower and upper limit of the 95 % CI were not estimable","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"46"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"description":"Duration of response of CR or PR based on investigator applies only to patients whose best overall response was CR or PR (RECIST 1.0). The start date was the date of first documented response (CR or PR) and the end date and censoring is defined the same as that for time to progression. Per RECIST criteria 1.0, CR: Disappearance of all target lesions; PR: At least a 30% decrease in the sum of the longest diameter of all target lesions, taking as reference the baseline sum of the longest diameters.","dispersionType":"95% Confidence Interval","groups":[{"description":"Everolimus 10 mg daily in combination with exemestane 25 mg daily","id":"OG000","title":"Everolimus + Exemestane"},{"description":"Placebo of everolimus in combination with exemestane 25 mg daily","id":"OG001","title":"Placebo + Exemestane"}],"paramType":"MEDIAN","populationDescription":"Randomized patients with best overall response of CR or PR.","reportingStatus":"POSTED","timeFrame":"21 months","title":"Duration of Response (Among Participants With Best Overall Response of CR or PR) Estimated Per Kaplan-Meier","type":"SECONDARY","unitOfMeasure":"Months"}